Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
CTI BioPharma Corp. CTIC
$8.94
-$0 (-0.06%)
На 18:00, 12 мая 2023
+16.33%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1178347800.00000000
-
week52high
8.95
-
week52low
3.55
-
Revenue
53948000
-
P/E TTM
-7
-
Beta
0.86159100
-
EPS
-0.81000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 20:00
Описание компании
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Jefferies | Buy | 01 сент 2022 г. | |
| Needham | Buy | Buy | 09 авг 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 09 авг 2022 г. |
| Cowen & Co. | Outperform | 07 июл 2022 г. | |
| Needham | Buy | Buy | 02 мар 2022 г. |
| SVB Leerink | Outperform | 17 окт 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Craig Adam R | D | 470054 | 2117 | 24 янв 2023 г. |
| Craig Adam R | D | 472171 | 83200 | 24 янв 2023 г. |
| Craig Adam R | A | 31557 | 2117 | 24 янв 2023 г. |
| Craig Adam R | D | 29440 | 2117 | 24 янв 2023 г. |
| Craig Adam R | A | 112640 | 83200 | 24 янв 2023 г. |
| Fong James K | D | 188000 | 100000 | 24 янв 2023 г. |
| Fong James K | D | 3565 | 100000 | 24 янв 2023 г. |
| Fong James K | A | 103565 | 100000 | 24 янв 2023 г. |
| Craig Adam R | D | 555371 | 84683 | 03 янв 2023 г. |
| Craig Adam R | D | 29440 | 84683 | 03 янв 2023 г. |
Новостная лента
CTI BioPharma skyrockets on acquisition by Sobi
Proactive Investors
10 мая 2023 г. в 11:13
CTI BioPharma shares added almost 85% on the news that the company would be acquired by Stockholm-based hematology and immunology leader Swedish Orphan Biovitrum AB (Sobi). Seattle-based CTI is a biopharmaceutical company focused on the development and commercialization of novel therapies for blood-related cancers.
Why Shares of CTI BioPharma Are Soaring Wednesday
The Motley Fool
10 мая 2023 г. в 10:51
CTI BioPharma has one FDA-approved therapy, Vonjo, to treat a rare form of bone marrow cancer. The company is being bought at a 89% premium from its closing price on Tuesday.
U.S. stock futures climb as inflation continues to cool
Market Watch
10 мая 2023 г. в 09:26
U.S. stock index futures climbed on Wednesday after data showed U.S. consumer price inflation cooled to lowest annual rate in two years in April, though the core inflation, which excludes food and energy prices, remains stickier.
Why Is CTI BioPharma (CTIC) Stock Up 85% Today?
InvestorPlace
10 мая 2023 г. в 08:25
CTI BioPharma (NASDAQ: CTIC ) stock is taking off on Wednesday after the company announced a major acquisition deal with Sobi. This deal has Sobi agreeing to acquire CTI BioPharma for $1.7 billion.
CTI BioPharma Soars After Agreeing $1.7 Billion Sale. Biotech Deals Keep Coming.
Barrons
10 мая 2023 г. в 07:05
Swedish Orphan Biovitrum will buy CTI for $9.10 a share as it looks to expand its rare hematology portfolio.